IBRX News and Press, ImmunityBio Inc. From 02/18/26

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, where no treatment was previously authorized for BCG-unrespon...

2026-02-18 05:12:10 ET Thesis ImmunityBio, Inc. ( IBRX ) stock has been on a very bullish run. The investor confidence comes from the potential of a chemo‑free immunotherapy platform, which is led by Anktiva. The short idea here is that Anktiva is an IL‑15 superagonist...

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Feb. 17, 2026 /CNW/ -- Equity-Insider.com   News Commentary – More than 2,100 oncology clinical trials...

Saudi FDA (SFDA) Encouraged Company to Submit Regulatory File for Recombinant BCG and Discussions Initiated for the Expansion of ANKTIVA ® in Combination with Checkpoint Inhibitors Across Multiple Tumor Types in the Kingdom of Saudi Arabia (KSA) ImmunityBio held productive regula...

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA ® and rituximab regimen to be evaluated in indolent non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia ResQ215B builds on a Phase 1 study that demonst...

Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC . , Jan. 28, 2026 /CNW/ --  USANewsGroup .com   News Commentary – As the global oncolo...

2026-01-27 09:00:00 ET The Undercovered Dozen is a weekly Seeking Alpha editor-curated series highlighting 12 articles on lesser-covered stocks from the previous seven days. We hope this provides ideas and inspires discussion among the community.... Read the full article on Seekin...

2026-01-24 11:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Wall Street Week Ahead, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings re...

2026-01-23 15:00:01 ET More on the markets Markets On Thin Ice: Greenland Framework, Japan's Yield Shock, And A Fragile Tape Trump 2.2: Can The Market Keep Rallying In His Second Year Of Presidency? Will U.S. Q4 Growth Exceed Q3's Strong Pace? Trump says U.S....

Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of 23 enrolled patients alive as of January 22, 2026 Fourteen patients have evaluable data, with the longest survival from time of disease recurrence reaching 12 months to date and o...